iBio (IBIO)
(Delayed Data from AMEX)
$1.88 USD
+0.10 (5.62%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $1.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for iBio, Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 7 | 34 | 97 | 55 |
Receivables | NA | 0 | 6 | 6 | 6 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 4 | 0 | 1 |
Other Current Assets | NA | 19 | 2 | 2 | 0 |
Total Current Assets | NA | 26 | 45 | 105 | 62 |
Net Property & Equipment | NA | 4 | 37 | 9 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 2 | 2 | 7 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 5 | 5 | 1 | 1 |
Deposits & Other Assets | NA | 0 | 6 | 0 | 0 |
Total Assets | NA | 41 | 99 | 147 | 94 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 1 | 0 |
Accounts Payable | NA | 2 | 4 | 2 | 2 |
Current Portion Long-Term Debt | NA | 13 | 22 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 4 | 3 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 0 | 0 | 2 |
Total Current Liabilities | NA | 22 | 30 | 7 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 32 | 32 |
Other Non-Current Liabilities | NA | 1 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 26 | 36 | 38 | 38 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 304 | 288 | 282 | 207 |
Retained Earnings | NA | -289 | -224 | -174 | -150 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 15 | 63 | 109 | 57 |
Total Liabilities & Shareholder's Equity | NA | 41 | 99 | 147 | 94 |
Total Common Equity | 0 | 15 | 63 | 109 | 57 |
Shares Outstanding | 8.60 | 1.00 | 0.40 | 0.40 | 0.20 |
Book Value Per Share | 0.00 | 15.38 | 158.73 | 271.43 | 283.05 |
Fiscal Year End for iBio, Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 6 | 4 | 5 | 7 |
Receivables | NA | 14 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 16 | 16 | 19 | 19 |
Total Current Assets | NA | 36 | 20 | 23 | 26 |
Net Property & Equipment | NA | 4 | 4 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 2 | 2 | 2 | 2 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 5 | 5 | 5 | 5 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 50 | 34 | 38 | 41 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 13 | 13 | 13 | 13 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 4 | 3 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 2 | 2 | 2 |
Total Current Liabilities | NA | 21 | 22 | 21 | 22 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 1 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 25 | 25 | 24 | 26 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 331 | 312 | 308 | 304 |
Retained Earnings | NA | -306 | -303 | -295 | -289 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 25 | 9 | 13 | 15 |
Total Liabilities & Shareholder's Equity | NA | 50 | 34 | 38 | 41 |
Total Common Equity | 0 | 25 | 9 | 13 | 15 |
Shares Outstanding | 8.60 | 8.50 | 3.20 | 1.40 | 1.00 |
Book Value Per Share | 0.00 | 2.92 | 2.88 | 9.44 | 15.38 |